The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Human Coagulation VIIa Market Research Report 2025
Synopsis
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
The global Recombinant Human Coagulation VIIa market was valued at US$ 1133.8 million in 2023 and is anticipated to reach US$ 1467.3 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Coagulation VIIa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Coagulation VIIa.
Report Scope
The Recombinant Human Coagulation VIIa market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Coagulation VIIa market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Coagulation VIIa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Coagulation VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Coagulation VIIa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
The global Recombinant Human Coagulation VIIa market was valued at US$ 1133.8 million in 2023 and is anticipated to reach US$ 1467.3 million by 2030, witnessing a CAGR of 3.7% during the forecast period 2024-2030.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Coagulation VIIa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Coagulation VIIa.
Report Scope
The Recombinant Human Coagulation VIIa market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Coagulation VIIa market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Coagulation VIIa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Coagulation VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Coagulation VIIa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Human Coagulation VIIa Market Overview
1.1 Product Overview and Scope of Recombinant Human Coagulation VIIa
1.2 Recombinant Human Coagulation VIIa Segment by Type
1.2.1 Global Recombinant Human Coagulation VIIa Market Value Comparison by Type (2024-2030)
1.2.2 Prefilled Syringe
1.2.3 Vial
1.3 Recombinant Human Coagulation VIIa Segment by Application
1.3.1 Global Recombinant Human Coagulation VIIa Market Value by Application: (2024-2030)
1.3.2 Congenital Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Others
1.4 Global Recombinant Human Coagulation VIIa Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Coagulation VIIa Revenue 2019-2030
1.4.2 Global Recombinant Human Coagulation VIIa Sales 2019-2030
1.4.3 Global Recombinant Human Coagulation VIIa Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Human Coagulation VIIa Market Competition by Manufacturers
2.1 Global Recombinant Human Coagulation VIIa Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Human Coagulation VIIa Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Human Coagulation VIIa Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Human Coagulation VIIa Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Type & Application
2.7 Recombinant Human Coagulation VIIa Market Competitive Situation and Trends
2.7.1 Recombinant Human Coagulation VIIa Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Coagulation VIIa Players Market Share by Revenue
2.7.3 Global Recombinant Human Coagulation VIIa Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Coagulation VIIa Retrospective Market Scenario by Region
3.1 Global Recombinant Human Coagulation VIIa Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Human Coagulation VIIa Global Recombinant Human Coagulation VIIa Sales by Region: 2019-2030
3.2.1 Global Recombinant Human Coagulation VIIa Sales by Region: 2019-2024
3.2.2 Global Recombinant Human Coagulation VIIa Sales by Region: 2025-2030
3.3 Global Recombinant Human Coagulation VIIa Global Recombinant Human Coagulation VIIa Revenue by Region: 2019-2030
3.3.1 Global Recombinant Human Coagulation VIIa Revenue by Region: 2019-2024
3.3.2 Global Recombinant Human Coagulation VIIa Revenue by Region: 2025-2030
3.4 North America Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.4.1 North America Recombinant Human Coagulation VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
3.4.3 North America Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Coagulation VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
3.5.3 Europe Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Coagulation VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Coagulation VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Coagulation VIIa Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Coagulation VIIa Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Human Coagulation VIIa Sales by Type (2019-2030)
4.1.1 Global Recombinant Human Coagulation VIIa Sales by Type (2019-2024)
4.1.2 Global Recombinant Human Coagulation VIIa Sales by Type (2025-2030)
4.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2019-2030)
4.2.1 Global Recombinant Human Coagulation VIIa Revenue by Type (2019-2024)
4.2.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2025-2030)
4.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Human Coagulation VIIa Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Human Coagulation VIIa Sales by Application (2019-2030)
5.1.1 Global Recombinant Human Coagulation VIIa Sales by Application (2019-2024)
5.1.2 Global Recombinant Human Coagulation VIIa Sales by Application (2025-2030)
5.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2019-2030)
5.2.1 Global Recombinant Human Coagulation VIIa Revenue by Application (2019-2024)
5.2.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2025-2030)
5.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Human Coagulation VIIa Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Recombinant Human Coagulation VIIa Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 LFB SA HEMA Biologics
6.2.1 LFB SA HEMA Biologics Corporation Information
6.2.2 LFB SA HEMA Biologics Description and Business Overview
6.2.3 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2019-2024)
6.2.4 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product Portfolio
6.2.5 LFB SA HEMA Biologics Recent Developments/Updates
6.3 AryoGen Pharmed
6.3.1 AryoGen Pharmed Corporation Information
6.3.2 AryoGen Pharmed Description and Business Overview
6.3.3 AryoGen Pharmed Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AryoGen Pharmed Recombinant Human Coagulation VIIa Product Portfolio
6.3.5 AryoGen Pharmed Recent Developments/Updates
6.4 GENERIUM
6.4.1 GENERIUM Corporation Information
6.4.2 GENERIUM Description and Business Overview
6.4.3 GENERIUM Recombinant Human Coagulation VIIa Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GENERIUM Recombinant Human Coagulation VIIa Product Portfolio
6.4.5 GENERIUM Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Coagulation VIIa Industry Chain Analysis
7.2 Recombinant Human Coagulation VIIa Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Coagulation VIIa Production Mode & Process
7.4 Recombinant Human Coagulation VIIa Sales and Marketing
7.4.1 Recombinant Human Coagulation VIIa Sales Channels
7.4.2 Recombinant Human Coagulation VIIa Distributors
7.5 Recombinant Human Coagulation VIIa Customers
8 Recombinant Human Coagulation VIIa Market Dynamics
8.1 Recombinant Human Coagulation VIIa Industry Trends
8.2 Recombinant Human Coagulation VIIa Market Drivers
8.3 Recombinant Human Coagulation VIIa Market Challenges
8.4 Recombinant Human Coagulation VIIa Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
